Skip to main content

West Pharmaceutical Services cash and equivalents

  • WST · NYSE
  • Medical devices
  • Health Care Supplies
  • S&P 500
$416.42+1.24%Close 13 Nov 2026

West Pharmaceutical Services's cash and equivalents was $791 million for fiscal year 2025 (the twelve months to 31 Dec 2025), up 63.3% from fiscal 2024.

In the third quarter of fiscal 2026 (the three months to 30 Sep 2026) it was $464 million, down 26.2% from a year earlier.

From West Pharmaceutical Services's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026.

Fiscal 2025
$791M
+63.3%
Q3 FY2026
$464M
−26.2% on a year
Growth over 9 years
+16.3%
a year, FY 2016–FY 2025

Cash and equivalents by fiscal year

$203MFY 2016$236MFY 2017+16.2%$337MFY 2018+43.0%$439MFY 2019+30.1%$616MFY 2020+40.2%$763MFY 2021+23.9%$894MFY 2022+17.3%$854MFY 2023−4.5%$485MFY 2024−43.2%$791MFY 2025+63.3%

Change on the year before, under each year. From FY 2016 to FY 2025, West Pharmaceutical Services's cash and equivalents went from $203 million to $791 million, a compound annual change of +16.3%; the highest was $894 million in FY 2022.

West Pharmaceutical Services cash and equivalents, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$203M$236M$337M$439M$616M$763M$894M$854M$485M$791M
Period end31 Dec 201631 Dec 201731 Dec 201831 Dec 201931 Dec 202031 Dec 202131 Dec 202231 Dec 202331 Dec 202431 Dec 2025

Cash and equivalents by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

West Pharmaceutical Services cash and equivalents, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Cash and equivalents$485M$404M$510M$629M$791M$521M$436M$464M
Period end31 Dec 202431 Mar 202530 Jun 202530 Sep 202531 Dec 202531 Mar 202630 Jun 202630 Sep 2026

How cash and equivalents is measured

Cash and equivalents is the cash the company holds at the end of the period and the investments it can turn into cash within three months. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

West Pharmaceutical Services's other figures

Cash and equivalents of comparable companies

Everything on WST, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.